Post by NEMERA

TirzePenVARIO showcased at CPHI China: advancing reliable solutions in the GLP‑1 space At CPHI China, Nemera showcases TirzePenVARIO, its solution for tirzepatide injections, belonging to the PenVARIO pen injector platform. As the GLP‑1 market continues to grow rapidly, speed, reliability, and risk mitigation remain key priorities for pharma partners. TirzePenVARIO is addressing these challenges: ✅ De-risked development Built on a marketed and verified platform, TirzePenVARIO helps reduce the level of development uncertainty and fosters accelerated timelines. ✅ Established compatibility Compatible with leading cartridge suppliers, enabling flexibility and smooth integration into existing partner ecosystems. ✅ Reliable high scale manufacturing Part of a well-established industrial setup, ensuring a reliable path to industrialization. ✅ Platform-driven efficiency Leveraging PenVARIO, a ready-to-use platform enabling fast time to market while ensuring robustness and scalability. TirzePenVARIO further strengthens Nemera’s position as a trusted partner in the GLP‑1 space, supporting customers in efficiently bringing therapies to cardiometabolic patients.